Skip to main content

Table 2 Binary logistic regression models for clinically significant portal hypertension (CSPH) using dichotomized and continuous variables for serum CYFRA21-1 in Patients with portal hypertension due to ACLD (cohort ii)

From: Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

  Serum CYFRA21-1, dichotomized ≥ 3.90 ng/mL Serum CYFRA21-1, per ng/mL increase
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Unadjusted 5.87 [2.95–11.68] < 0.001 1.73 [1.40–2.14] < 0.001
Adjusted for age and sex 6.19 [3.09–12.39] < 0.001 1.77 [1.42–2.20] < 0.001
Adjusted for etiology 5.25 [2.58–10.70] < 0.001 1.73 [1.38–2.18] < 0.001
Adjusted for age, sex, and etiology 5.47 [2.65–11.29] < 0.001 1.79 [1.41–2.28] < 0.001
Adjusted for platelet count 6.74 [3.19–14.22] < 0.001 1.75 [1.40–2.18] < 0.001
Adjusted for MELD score 4.07 [1.99–8.33] < 0.001 1.53 [1.23–1.90] < 0.001
  1. CSPH was defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg. CYFRA21-1 was dichotomized using a cut-off determined by the maximum Youden index for the presence of CSPH. Abbreviations: CYFRA21-1 fragments of keratin 19, MELD model for end-stage liver disease